Sébastien Roux Selected Research

clazosentan

5/2020	Thick and diffuse cisternal clot independently predicts vasospasm-related morbidity and poor outcome after aneurysmal subarachnoid hemorrhage.
8/2019	Reversal of Vasospasm with Clazosentan After Aneurysmal Subarachnoid Hemorrhage: A Pilot Study.
1/2013	Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2).
6/2012	Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling.
7/2011	Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sébastien Roux Research Topics

Disease

5	Cerebral Infarction 05/2020 - 12/2010
4	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 05/2020 - 06/2012
3	Autistic Disorder (Autism) 03/2019 - 01/2018
3	Hypotension (Low Blood Pressure) 01/2013 - 07/2011
2	Intracranial Vasospasm 05/2020 - 08/2019
2	Anemia 01/2013 - 06/2012
2	Idiopathic Pulmonary Fibrosis 07/2011 - 01/2008
2	Dyspnea (Shortness of Breath) 07/2011 - 01/2008
2	Disease Progression 01/2008 - 07/2002
1	Ischemia 05/2020
1	Infarction (Infarctions) 05/2020
1	Left Ventricular Dysfunction 08/2019
1	Retinal Detachment (Retinal Detachments) 08/2013
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2013
1	Ruptured Aneurysm 07/2011
1	Heart Failure 07/2002
1	Pulmonary Arterial Hypertension 07/2002
1	Clinical Deterioration 07/2002
1	Familial Primary Pulmonary Hypertension 07/2002
1	Vascular Diseases (Vascular Disease) 07/2002

Drug/Important Bio-Agent (IBA)

5	clazosentanIBA 05/2020 - 07/2011
3	Valproic Acid (Depakote)FDA LinkGeneric 03/2019 - 01/2018
3	Endothelin Receptor AntagonistsIBA 01/2013 - 07/2002
3	Bosentan (Tracleer)FDA Link 07/2011 - 07/2002
1	Endothelin A ReceptorIBA 08/2019
1	CalbindinsIBA 01/2019
1	AcidsIBA 01/2019
1	Retinaldehyde (Retinal)IBA 08/2013
1	CollagenIBA 07/2002
1	Endothelins (Endothelin)IBA 07/2002
1	Peptides (Polypeptides)IBA 07/2002

Therapy/Procedure

5	Therapeutics 05/2020 - 12/2010
1	Aftercare (After-Treatment) 01/2013